2003
Outcome After Pancreaticoduodenectomy for Periampullary Cancer: An Analysis from the Veterans Affairs National Surgical Quality Improvement Program
Billingsley K, Hur K, Henderson W, Daley J, Khuri S, Bell R. Outcome After Pancreaticoduodenectomy for Periampullary Cancer: An Analysis from the Veterans Affairs National Surgical Quality Improvement Program. Journal Of Gastrointestinal Surgery 2003, 7: 484-491. PMID: 12763405, DOI: 10.1016/s1091-255x(03)00067-2.Peer-Reviewed Original ResearchConceptsNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramVeterans Affairs Healthcare SystemQuality Improvement ProgramPeriampullary cancerAdverse outcomesRisk factorsVeterans Affairs National Surgical Quality Improvement ProgramVA National Surgical Quality Improvement ProgramPre-defined complicationsPostoperative mortality ratePreoperative risk factorsPreoperative serum albuminMain outcome measuresRisk-adjusted comparisonsDifferent health care systemsVA Medical CenterLogistic regression analysisHealth care systemPancreaticoduodenectomy outcomesPostoperative mortalityAnesthesiologists classificationPostoperative deathsSeptic complicationsIntraoperative variables
2001
The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population
Billingsley K, Maynard C, Schwartz D, Dominitz J. The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population. Cancer 2001, 92: 1272-1280. PMID: 11571743, DOI: 10.1002/1097-0142(20010901)92:5<1272::aid-cncr1448>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsOperable esophageal carcinomaTrimodality therapyEsophageal carcinomaPerioperative mortalityDistal esophageal tumorsOutpatient clinic filesOutcomes of patientsRetrospective cohort studyOverall perioperative mortalityFavorable prognostic factorPredictors of survivalAbsence of metastasesMain outcome measuresPatient Treatment FileRecord Locator SystemType of treatmentHealth care systemInduction chemoradiotherapyMidesophageal tumorsNeoadjuvant chemoradiotherapyCohort studyMedian survivalOverall survivalPatient ageSurgical therapy